Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference Life Science Investing
Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy at 27th Annual NMSG Scientific Meeting Life Science Investing
Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences Life Science Investing
Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York Medical Device Investing
Medicenna to Present at the H.C. Wainwright 28th Annual Global Investment Conference Life Science Investing
C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society Annual Meeting Life Science Investing
Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy Life Science Investing
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026 Life Science Investing
Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China Life Science Investing
